Aclaris stock falls after atopic dermatitis trial fails

Aclaris Therapeutics (NASDAQ:ACRS) shares dropped 6% after its Phase 2 ADMIRATION trial for atopic dermatitis treatment failed to meet primary and secondary endpoints. The trial evaluated bosakitug (ATI-045), which showed target engagement but did not improve Eczema Area and Severity Index scores. The company remains focused on other treatments, including modzatinib (ATI-2138) for lichen planus, with a Phase 2b trial underway.

Original reporting
Published Nov 16, 2026, 4:22 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 4:28 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$ACRS
Bearish
high confidence
Mentioned
$ACRS
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$ACRSBearishHigh
01

Why it matters

The failure underscores the difficulty of targeting TSLP alone in atopic dermatitis and may lead to a re‑evaluation of the company's pipeline valuation.

02

Market read

The trial miss is a material, first‑time disclosure that moved the stock down 6% intraday, offering a clear short‑term trading signal.

03

What to watch

Fast Track designation for its lichen planus program may provide a near‑term catalyst that could offset the trial disappointment.

Relevance 8/10Novelty 8/10Timing: today

Background

Aclaris Therapeutics (NASDAQ:ACRS) is a clinical‑stage biotech focused on dermatology and immunology. The ADMIRATION trial was a key study for its anti‑TSLP antibody.

Company-level read

Ticker impact

$ACRSBearishHigh confidence
Context

Aclaris Therapeutics reported its Phase 2 ADMIRATION trial for atopic dermatitis failed to meet primary and secondary endpoints, causing a 6% share drop.

Expected impact

likely pressure as the market prices in the negative trial outcome

Evidence & confidence

First disclosure of a pivotal Phase 2 failure for a biotech; the stock already fell 6% on the news, indicating immediate sell pressure.

Market effects

May dampen sentiment for other atopic dermatitis and skin‑disease biotech peers.

Limited to U.S. biotech sector; no broader regional effect.

Low global impact; primarily relevant to investors in biotech and specialty pharma.

Counterpoint

If the company can successfully pivot to its oral kinase programs, the stock could recover on future data releases.

Key entities

  • Aclaris Therapeutics Inc

    Clinical‑stage biotech developing dermatology and immunology therapies.

  • Neal Walker

    CEO of Aclaris Therapeutics, quoted on the trial outcome.

Related articles

$ACRSMedAI 8/10

Wedbush cuts Aclaris Therapeutics stock rating on trial miss

Wedbush downgraded Aclaris Therapeutics (ACRS) to Neutral, cutting its price target to $3.00 from $8.00 after a Phase 2 trial failure. The stock is down 13% over the past week. Wedbush expects Aclaris to shift focus to eosinophilic esophagitis but notes growing competition. Other analysts have mixed views on ACRS's pipeline and potential.

$CGONMed

Biotech's Monday Split: Two Trial Wins, One Trial Miss and an FDA Rejection

Biotech stocks moved amid clinical and regulatory news. CG Oncology's bladder cancer drug met its primary endpoint, reducing recurrence risk by 68%. Lexeo's gene therapy showed promising interim data. Summit Therapeutics' lung cancer drug received an FDA rejection, and Aclaris' atopic dermatitis treatment missed Phase 2 goals. The S&P 500 and Nasdaq fell 1.92% and 2.49%, respectively, according to CNBC.

$ACRSHighAI 8/10

Aclaris Therapeutics’ mAb fails in Phase II eczema trial

Aclaris Therapeutics' Phase II trial of bosakitug for atopic dermatitis failed to meet primary and secondary endpoints, though the drug showed target engagement. The company remains focused on other treatments, including modzatinib and ATI-052. The atopic dermatitis market is projected to grow to $21.5bn by 2033, with key players like Sanofi and AbbVie.

$ACRSMed

Aclaris Therapeutics Reports Phase 2 Bosakitug Miss and Advances Lichen Planus Trial

Aclaris Therapeutics reported that bosakitug failed to meet primary and secondary endpoints in its Phase 2 atopic dermatitis trial but was well tolerated. The company advanced its clinical pipeline, initiating a Phase 2b trial for modzatinib in lichen planus and planning Phase 1 and 2b trials for ATI-9494 and ATI-052, respectively, in 2027. According to the company, bosakitug showed target engagement and reduced immune-activation biomarkers.